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Axillary implantation of Impella CP allows early rehabilitation of 
patients in cardiogenic shock bridged to heart transplantation. 
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Introduction: Axillary implantation of Impella CP device (Abiomed, Inc) is a novel implantationmethod for 
patients in cardiogenic shock (CS), which facilitates a better placement of the device and allows mobilization of 
patients while on support. 
Purpose: To describe our pilot experience using axillary implantation of Impella CP as a bridge to heart 
transplantation (HT) allowing better rehabilitation on support. 
Methods: Retrospective single-centre descriptive study of CS patients bridged to HT on support with Impella® 
CP through axillary artery between March and December of 2016. We collect data about survival, time of 
mechanical ventilation after HT, days in ICU, days to hospital discharge and major complications including 
bleeding or infection. 
Results: 4 patients were bridged to HT with a transaxillary Impella® CP. Data of patients are in the table below. 
All Impella CP devices were surgically implanted using a Dacron graft. Patients 1, 2 and 3 had received an 
intraaortic balloon pump before Impella® CP. All patients were extubated immediately after Impella® CP 
implantation and started an early rehabilitation program consistent in kinesitherapy, respiratory physiotherapy 
and active movements. Median time on device support was 13.5 days (IQR 11.25 to 15.5). In one patient the 
device had to be repositioned because of displacement. Median time of ICU stay after HT was 7.5 days (IQR 5.5 
to 9.75 days) and median time to hospital discharge after HT was 29.5 days (IQR 26 to 33.5 days). All patients 
were discharged alive. Major complications after HT were bleeding in one patient with cardiac tamponade and 
an ischemic stroke in other patient with significant bilateral carotid stenosis. Patient recovered without 
neurologic sequelae. 
Conclusion: Axillary implantation of Impella® CP seems to be a valid strategy for bridging patients in 
INTERMACS 1 and 2 for HT allowing early initiation of rehabilitation therapy while on support. 
P 144 Patients bridged to HT 
Patient  Gender  Age  Heart condition  
INTERMACS 
profile at 
implantation 
Time of 
support 
(days) 
Intubation 
after HT 
(hours) 
ICU stay  
after HT 
(days) 
Days to 
discharge 
after HT 
Complications 
          
1  Male  65  Idiopathic dilated 
cardiomyopaty 
2  20  11  6  30  Cardiac 
tamponade 
2  Male  68  Ischemic 
cardiomyopathy  
1  6  72  9  44  Ischemic 
stroke 
3  Male  55  Idiopathic dilated 
cardiomyopathy 
2  13  96  12  29  None 
4  Male  56  Eosinophilic 
myocarditis  
2  14  12  4  17  None 
          
 
ICU: Intensive care unit; HT: Heart transplant. 
